Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure

Of the various medical therapies for heart failure (HF), sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor that combines sacubitril, a pro-drug that is further metabolized to the neprilysin inhibitor sacubitrilat, and the angiotensin II type 1 receptor blocker valsar...

Descripción completa

Detalles Bibliográficos
Autores principales: Litwin, Sheldon E., East, Cara A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815716/
https://www.ncbi.nlm.nih.gov/pubmed/36620638
http://dx.doi.org/10.3389/fcvm.2022.1058998

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815716/
https://www.ncbi.nlm.nih.gov/pubmed/36620638
http://dx.doi.org/10.3389/fcvm.2022.1058998

Ejemplares similares